Abstract 839P
Background
Axi-cel is a chimeric antigen receptor T-cell (CAR T) therapy evaluated in ZUMA-1 while glofit is a bispecific antibody evaluated in NP30179. Without direct evidence, we estimated relative treatment effects of axi-cel versus glofit in 3L+ R/R LBCL using an unanchored MAIC.
Methods
A logistic propensity score model was used to weigh ZUMA-1 patient-level data to match the baseline characteristics of NP30179 (N=155) on pre-specified clinically relevant prognostic factors: ECOG performance status, disease stage, response to last therapy, prior lines of therapy, lactate dehydrogenase, primary refractoriness, LBCL subtype, and prior autologous stem cell transplant. Outcomes were objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and grade ≥3 (G3+) cytokine release syndrome (CRS) and neurological events (NE). Relative effects were hazard/odds ratios (HR/OR). Base case analyses included ZUMA-1 pivotal Cohorts 1+2 (C12; N=101) while scenario analyses of OS, CRS, and NE included ZUMA-1 safety Cohorts 4+6 (C1246; N=182).
Results
Axi-cel improved ORR and PFS versus glofit (Table; effective sample size [ESS] = 32). Median PFS for axi-cel versus glofit were 15 and 11.4 months, respectively. DOR and OS were comparable with point estimates favoring axi-cel. In the scenario analysis, OS was also improved with axi-cel (ESS = 63). Axi-cel was associated with higher rates of G3+ CRS and NEs but the former was comparable in the scenario analysis.
Table: 839P
MAIC results
Outcome | Weighted axi-cel versus glofitamab (95% confidence interval) | |
Base case (C12) ESS=32 | Scenario (C1246) ESS=63 | |
ORR OR | 2.32 (1.01−5.33) | N/A |
PFS HR | 0.62 (0.40−0.96) | N/A |
DOR HR | 0.72 (0.35−1.48) | N/A |
OS HR | 0.70 (0.42−1.18) | 0.63 (0.42−0.95) |
G3+ CRS OR | 4.93 (1.42−17.08) | 2.83 (0.89−8.97) |
G3+ NE OR | 22.59 (7.25−70.36) | 15.54 (5.53−43.63) |
Conclusions
Findings suggests axi-cel may be more efficacious in terms of ORR and PFS compared to glofit but with a higher risk of certain adverse events. Of note, median follow-up was shorter in NP30179 (12.6 months) than ZUMA-1 (60 months [C12] and 24 months [C46]) and differences in prior CAR T use could not be accounted for (34% in NP30179 versus 0% in ZUMA-1).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kite, a Gilead Company.
Funding
Kite, a Gilead Company.
Disclosure
F.L. Locke: Financial Interests, Institutional, Advisory Role, Honoraria from Gilead and Pfizer; scientific advisory role and consultant to AbbVie, ADC, Curio Science, Epizyme, Gilead, Janssen, Kite, a Gilead Company, Pfizer, Nektar, Novartis, Syncopation, and TGR therapeutics: Kite Pharma. J.M. Chen, K. Chan, I. Zhang, S. Keeping: Financial Interests, Institutional, Full or part-time Employment, PRECISIONheor received consulting fees from Kite, a Gilead Company: PRECISIONheor. M.D. Ray, C. Fu, A.R. Patel: Financial Interests, Personal and Institutional, Full or part-time Employment, Is a stockholder and current employee of Kite, a Gilead Company: Kite Pharma. O.O. Oluwole: Financial Interests, Institutional, Advisory Role, Scientific advisory role and consultant to Kite Pharma, Allogene, CERo Therapeutics, Novartis, BlueBird Bio, Bristol Myers Squibb, National Cancer Institute, Leukemia and Lymphoma Society: Kite Pharma.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18